NB-NC-1 |
Non-neoplastic breast from patients without breast carcinoma |
19 |
B |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-2 |
Non-neoplastic breast from patients without breast carcinoma |
24 |
B |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-3 |
Non-neoplastic breast from patients without breast carcinoma |
25 |
W |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-4 |
Non-neoplastic breast from patients without breast carcinoma |
26 |
B |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-5 |
Non-neoplastic breast from patients without breast carcinoma |
43 |
W |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-6 |
Non-neoplastic breast from patients without breast carcinoma |
38 |
B |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-NC-7 |
Non-neoplastic breast from patients without breast carcinoma |
23 |
B |
N/A |
N/A |
N/A |
N/A |
N/A |
|
NB-C-1 |
Non-neoplastic from breast carcinoma patients |
68 |
W |
pT1a |
snpN0 |
positive |
positive |
negative |
|
NB-C-2 |
Non-neoplastic from breast carcinoma patients |
60 |
W |
mpT1c |
snpN0 |
positive |
positive |
negative |
|
NB-C-3 |
Non-neoplastic from breast carcinoma patients |
67 |
W |
pT2 |
pN0 |
positive |
positive |
negative |
ICL-2 |
NB-C-4 |
Non-neoplastic from breast carcinoma patients |
59 |
W |
pT2 |
pN0 |
positive |
positive |
positive |
IDC-H-3 |
NB-C-5 |
Non-neoplastic from breast carcinoma patients |
44 |
|
pT1c |
pN0 |
positive |
negative |
negative |
|
NB-C-6 |
Non-neoplastic from breast carcinoma patients |
39 |
W |
pTis(DCIS) |
|
positive |
|
|
|
NB-C-7 |
Non-neoplastic from breast carcinoma patients |
47 |
W |
pT1c |
snpN0 |
positive |
positive |
negative |
IDC-L-5 |
DCIS-L-1 |
Ductal carcinoma in situ, low grade |
60 |
B |
pTis(DCIS) |
snpN0 |
positive |
|
|
|
DCIS-L-2 |
Ductal carcinoma in situ, low grade |
64 |
B |
pTis(DCIS) |
|
positive |
|
|
|
DCIS-L-3 |
Ductal carcinoma in situ, low grade |
43 |
W |
pT1b |
pN0 |
positive |
positive |
negative |
|
DCIS-L-4 |
Ductal carcinoma in situ, low grade |
43 |
W |
pTis(DCIS) |
snpN0 |
positive |
|
|
|
DCIS-L-5 |
Ductal carcinoma in situ, low grade |
51 |
W |
pT1c |
snpN0 |
positive |
positive |
negative |
|
DCIS-L-6 |
Ductal carcinoma in situ, low grade |
54 |
|
pTis(DCIS) |
pNx |
positive |
|
|
|
DCIS-L-7 |
Ductal carcinoma in situ, low grade |
58 |
W |
pTis(DCIS) |
snpN0 |
positive |
positive |
|
|
DCIS-H-1 |
Ductal carcinoma in situ, high grade |
48 |
B |
pTis(DCIS) |
|
positive |
|
|
|
DCIS-H-2 |
Ductal carcinoma in situ, high grade |
50 |
W |
pTis(DCIS) |
|
positive |
|
|
|
DCIS-H-3 |
Ductal carcinoma in situ, high grade |
73 |
W |
pTis(DCIS) |
snpN0 |
positive |
|
|
|
DCIS-H-4 |
Ductal carcinoma in situ, high grade |
82 |
B |
pT2 |
snpN0 |
negative |
negative |
negative |
|
DCIS-H-5 |
Ductal carcinoma in situ, high grade |
42 |
W |
pT1c |
pN2a |
positive |
positive |
negative |
|
DCIS-H-6 |
Ductal carcinoma in situ, high grade |
56 |
W |
ypTis(DCIS) |
ypN0 |
negative |
positive |
positive |
|
DCIS-H-7 |
Ductal carcinoma in situ, high grade |
37 |
B |
pTis(DCIS) |
pN1a |
positive |
positive |
negative |
|
IDC-L-1 |
Invasive ductal carcinoma, grade 1 or 2 |
57 |
B |
pT2 |
pN0 |
positive |
positive |
positive |
|
IDC-L-2 |
Invasive ductal carcinoma, grade 1 or 2 |
48 |
W |
ypT1c |
pN2a |
positive |
negative |
negative |
LMN-6 |
IDC-L-3 |
Invasive ductal carcinoma, grade 1 or 2 |
61 |
W |
pT1c |
pN0 |
positive |
positive |
negative |
|
IDC-L-4 |
Invasive ductal carcinoma, grade 1 or 2 |
31 |
W |
pT2 |
snpN0 |
positive |
positive |
negative |
|
IDC-L-5 |
Invasive ductal carcinoma, grade 1 or 2 |
47 |
B |
pT1c |
snpN0 |
positive |
positive |
negative |
|
IDC-L-6 |
Invasive ductal carcinoma, grade 1 or 2 |
48 |
W |
pT2 |
pN2a |
positive |
positive |
negative |
NB-C-7 |
IDC-L-7 |
Invasive ductal carcinoma, grade 1 or 2 |
70 |
W |
pT2 |
pN3a |
positive |
positive |
negative |
|
IDC-H-1 |
Invasive ductal carcinoma, grade 3 |
58 |
B |
ypT2 |
ypN1a |
negative |
negative |
negative |
|
IDC-H-2 |
Invasive ductal carcinoma, grade 3 |
58 |
O |
ypT2 |
ypN2a |
positive |
positive |
negative |
LNM-1 |
IDC-H-3 |
Invasive ductal carcinoma, grade 3 |
59 |
W |
pT2 |
pN0 |
positive |
positive |
positive |
NB-C-4 |
IDC-H-4 |
Invasive ductal carcinoma, grade 3 |
77 |
W |
pT3 |
pN1a |
positive |
positive |
negative |
|
IDC-H-5 |
Invasive ductal carcinoma, grade 3 |
79 |
W |
ypT4b |
ypN1a |
positive |
positive |
positive |
LNM-7 |
IDC-H-6 |
Invasive ductal carcinoma, grade 3 |
64 |
W |
pT1b |
snpN0 |
negative |
negative |
negative |
|
IDC-H-7 |
Invasive ductal carcinoma, grade 3 |
46 |
W |
pT2 |
pN0 |
negative |
negative |
positive |
|
ILC-1 |
Invasive lobular carcinoma |
49 |
W |
pT1c |
pN0 |
positive |
positive |
negative |
|
ILC-2 |
Invasive lobular carcinoma |
67 |
W |
pT2 |
pN0 |
positive |
positive |
negative |
NB-C-3 |
ILC-3 |
Invasive lobular carcinoma |
65 |
W |
pT2 |
pN0 |
positive |
positive |
negative |
|
ILC-4 |
Invasive lobular carcinoma |
64 |
W |
pT1c |
pN1a |
positive |
positive |
negative |
|
ILC-5 |
Invasive lobular carcinoma |
59 |
B |
ypT2 |
ysnpN0 |
positive |
positive |
negative |
|
ILC-6 |
Invasive lobular carcinoma |
76 |
W |
pT2 |
pN3a |
positive |
negative |
negative |
|
ILC-7 |
Invasive lobular carcinoma |
75 |
W |
pT1c |
pN0 |
positive |
positive |
negative |
|
LNM-1 |
Breast carcinoma metastatic to regional lymph nodes |
58 |
O |
ypT2 |
ypN2a |
positive |
positive |
negative |
IDC-H-2 |
LNM-2 |
Breast carcinoma metastatic to regional lymph nodes |
85 |
W |
pT4b |
pN1a |
positive |
positive |
negative |
|
LNM-3 |
Breast carcinoma metastatic to regional lymph nodes |
39 |
B |
pT2 |
pN2a |
positive |
positive |
negative |
|
LNM-4 |
Breast carcinoma metastatic to regional lymph nodes |
54 |
B |
pT1a |
pN1a |
positive |
positive |
negative |
|
LNM-5 |
Breast carcinoma metastatic to regional lymph nodes |
62 |
W |
pT1c |
pN3a |
negative |
negative |
negative |
|
LNM-6 |
Breast carcinoma metastatic to regional lymph nodes |
48 |
W |
pT1c |
pN2a |
positive |
negative |
negative |
IDC-L-2 |
LNM-7 |
Breast carcinoma metastatic to regional lymph nodes |
79 |
W |
ypT4b |
ypN1a |
positive |
positive |
positive |
IDC-H-5 |
|
|
|
Race: W = white, B = black, O = other non-white |
|
|
*American Joint Committee on Cancer Cancer Staging Manual, 7th Ed. |
|
|
†ER & PR: negative = <1%+, positive = ≥1%+, blank = not tested |
|
|
††Her2: negative = not amplified, positive = amplified, blank = not tested |